Literature DB >> 23243309

Insulin-like growth factor (IGF) signaling requires αvβ3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation.

Masaaki Fujita1, Yoko K Takada, Yoshikazu Takada.   

Abstract

Integrin αvβ3 plays a role in insulin-like growth factor 1 (IGF1) signaling (integrin-IGF1 receptor (IGF1R) cross-talk) in non-transformed cells in anchorage-dependent conditions. We reported previously that IGF1 directly binds to αvβ3 and induces αvβ3-IGF1-IGF1R ternary complex formation in these conditions. The integrin-binding defective IGF1 mutant (R36E/R37E) is defective in inducing ternary complex formation and IGF signaling, whereas it still binds to IGF1R. We studied if IGF1 can induce signaling in anchorage-independent conditions in transformed Chinese hamster ovary cells that express αvβ3 (β3-CHO) cells. Here we describe that IGF1 signals were more clearly detectable in anchorage-independent conditions (polyHEMA-coated plates) than in anchorage-dependent conditions. This suggests that IGF signaling is masked by signals from cell-matrix interaction in anchorage-dependent conditions. IGF signaling required αvβ3 expression, and R36E/R37E was defective in inducing signals in polyHEMA-coated plates. These results suggest that αvβ3-IGF1 interaction, not αvβ3-extracellular matrix interaction, is essential for IGF signaling. Inhibitors of IGF1R, Src, AKT, and ERK1/2 did not suppress αvβ3-IGF-IGF1R ternary complex formation, suggesting that activation of these kinases are not required for ternary complex formation. Also, mutations of the β3 cytoplasmic tail (Y747F and Y759F) that block β3 tyrosine phosphorylation did not affect IGF1R phosphorylation or AKT activation. We propose a model in which IGF1 binding to IGF1R induces recruitment of integrin αvβ3 to the IGF-IGF1R complex and then β3 and IGF1R are phosphorylated. It is likely that αvβ3 should be together with the IGF1-IGF1R complex for triggering IGF signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23243309      PMCID: PMC3561530          DOI: 10.1074/jbc.M112.412536

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Changing ligand specificities of alphavbeta1 and alphavbeta3 integrins by swapping a short diverse sequence of the beta subunit.

Authors:  J Takagi; T Kamata; J Meredith; W Puzon-McLaughlin; Y Takada
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

Review 2.  Cell migration: interactions among integrins, IGFs and IGFBPs.

Authors:  J I Jones; M E Doerr; D R Clemmons
Journal:  Prog Growth Factor Res       Date:  1995

3.  A microplate assay for quantitation of anchorage-independent growth of transformed cells.

Authors:  H Fukazawa; S Mizuno; Y Uehara
Journal:  Anal Biochem       Date:  1995-06-10       Impact factor: 3.365

4.  Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival.

Authors:  E Petitclerc; S Strömblad; T L von Schalscha; F Mitjans; J Piulats; A M Montgomery; D A Cheresh; P C Brooks
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

5.  Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis.

Authors:  S Strömblad; J C Becker; M Yebra; P C Brooks; D A Cheresh
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

Review 6.  Interaction between insulin-like growth factor-I receptor and alphaVbeta3 integrin linked signaling pathways: cellular responses to changes in multiple signaling inputs.

Authors:  D R Clemmons; L A Maile
Journal:  Mol Endocrinol       Date:  2004-11-04

7.  The effect of extracellular matrix proteins on porcine smooth muscle cell insulin-like growth factor (IGF) binding protein-5 synthesis and responsiveness to IGF-I.

Authors:  B Zheng; C Duan; D R Clemmons
Journal:  J Biol Chem       Date:  1998-04-10       Impact factor: 5.157

8.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.

Authors:  M Friedlander; C L Theesfeld; M Sugita; M Fruttiger; M A Thomas; S Chang; D A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.

Authors:  P C Brooks; S Strömblad; R Klemke; D Visscher; F H Sarkar; D A Cheresh
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

10.  An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice.

Authors:  F Mitjans; D Sander; J Adán; A Sutter; J M Martinez; C S Jäggle; J M Moyano; H G Kreysch; J Piulats; S L Goodman
Journal:  J Cell Sci       Date:  1995-08       Impact factor: 5.285

View more
  14 in total

Review 1.  Crosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1.

Authors:  Yoshikazu Takada; Yoko K Takada; Masaaki Fujita
Journal:  Cytokine Growth Factor Rev       Date:  2017-02-03       Impact factor: 7.638

2.  Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1.

Authors:  Masaaki Fujita; Kan Zhu; Chitose K Fujita; Min Zhao; Kit S Lam; Mark J Kurth; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2014-11-14       Impact factor: 5.157

3.  Direct binding to integrins and loss of disulfide linkage in interleukin-1β (IL-1β) are involved in the agonistic action of IL-1β.

Authors:  Yoko K Takada; Jessica Yu; Masaaki Fujita; Jun Saegusa; Chun-Yi Wu; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2017-10-13       Impact factor: 5.157

4.  β1 integrin is a crucial regulator of pancreatic β-cell expansion.

Authors:  Giuseppe R Diaferia; Antonio J Jimenez-Caliani; Prerana Ranjitkar; Wendy Yang; Gary Hardiman; Christopher J Rhodes; Laura Crisa; Vincenzo Cirulli
Journal:  Development       Date:  2013-07-17       Impact factor: 6.868

5.  An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.

Authors:  Masaaki Fujita; Katsuaki Ieguchi; Dora M Cedano-Prieto; Andrew Fong; Charles Wilkerson; Jane Q Chen; Mac Wu; Su-Hao Lo; Anthony T W Cheung; Machelle D Wilson; Robert D Cardiff; Alexander D Borowsky; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2013-05-21       Impact factor: 5.157

6.  Autoregulation of insulin receptor signaling through MFGE8 and the αvβ5 integrin.

Authors:  Ritwik Datta; Carlos O Lizama; Amin K Soltani; William Mckleroy; Michael J Podolsky; Christopher D Yang; Tony L Huynh; Kelly M Cautivo; Biao Wang; Suneil K Koliwad; Nada A Abumrad; Kamran Atabai
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-04       Impact factor: 11.205

Review 7.  Fibronectin at select sites binds multiple growth factors and enhances their activity: expansion of the collaborative ECM-GF paradigm.

Authors:  Jia Zhu; Richard A F Clark
Journal:  J Invest Dermatol       Date:  2013-12-12       Impact factor: 8.551

Review 8.  Integrins in the Spotlight of Cancer.

Authors:  Daniela Bianconi; Matthias Unseld; Gerald W Prager
Journal:  Int J Mol Sci       Date:  2016-12-06       Impact factor: 5.923

9.  Enhanced Expression of Integrin αvβ3 Induced by TGF-β Is Required for the Enhancing Effect of Fibroblast Growth Factor 1 (FGF1) in TGF-β-Induced Epithelial-Mesenchymal Transition (EMT) in Mammary Epithelial Cells.

Authors:  Seiji Mori; Moe Kodaira; Ayano Ito; Mika Okazaki; Naomasa Kawaguchi; Yoshinosuke Hamada; Yoshikazu Takada; Nariaki Matsuura
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

10.  Sulfatide interacts with and activates integrin αVβ3 in human hepatocellular carcinoma cells.

Authors:  Rong Wang; Bing Qi; Yi Wei Dong; Qian Qian Cai; Nian Hui Deng; Qi Chen; Chao Li; Yu Tong Jin; Xing Zhong Wu
Journal:  Oncotarget       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.